Company Encyclopedia
View More
name
Amgen
AMGN.US
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
1.945 T
AMGN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking52/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE81.71%A
    • Profit Margin19.47%A
    • Gross Margin71.29%A
  • Growth ScoreB
    • Revenue YoY10.56%B
    • Net Profit YoY65.60%B
    • Total Assets YoY-0.82%D
    • Net Assets YoY27.79%A
  • Cash ScoreB
    • Cash Flow Margin513.50%C
    • OCF YoY10.56%B
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreE
    • Gearing Ratio89.33%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN

    Tema Etfs LLC increased its holdings in Amgen Inc. by 33.3% in Q2, owning 12,977 shares worth $3.62 million. Analysts have mixed ratings on Amgen, with a consensus target price of $335.65. Amgen reported strong quarterly earnings, beating estimates with $5.64 EPS and $9.56 billion revenue. The company announced a quarterly dividend of $2.38 per share, yielding 2.8%. Amgen's stock performance shows a one-year high of $346.38.

    Market Beat·
    US
    AMGN
    -2.68%
    Market Beat·
    US
    AMGN
    -2.68%

    First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN

    First Trust Advisors LP reduced its stake in Amgen Inc. by 3.8% in Q2, selling 21,347 shares. Amgen's stock opened at $340.16, with a market cap of $183.17 billion. The company reported Q3 earnings of $5.64 per share, beating estimates, and announced a quarterly dividend of $2.38. Insiders sold shares, including EVP Murdo Gordon and SVP Rachna Khosla.

    Market Beat·
    US
    AMGN
    -2.68%
    Market Beat·
    US
    AMGN
    -2.68%

    Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

    Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

    Dow Jones·
    US
    JNJ
    -0.10%
    US
    AMGN
    -2.68%
    US
    ABBV
    -1.08%
    Dow Jones·
    US
    JNJ
    -0.10%
    US
    AMGN
    -2.68%
    US
    ABBV
    -1.08%

    The S&P 500 Index closed up 0.3% preliminarily, with the energy sector rising 1.8%, the financial sector up 1.2%, the consumer discretionary sector up 0.8%, the telecommunications sector up 0.2%, and the technology sector down 0.4%. The Nasdaq 100 Index closed up 0.2% preliminarily, with Microchip Tech rising 12.7%, ON Semiconductor up 10.8%, Marvell Technology up 7.6%, Meta down 1.1%, Micron and Microsoft down 2.3%, Regeneron Pharma down 2.5%, PayPal down 2.7%, TTD down 3.2%, and Netflix down 4.9%. UnitedHealth rose 4.9%, Goldman Sachs rose 2.6%, McDonald's, American Express, and Amgen all rose at least 2%, NVIDIA down 1%, and Boeing down 1.5%

    Wallstreetcn·
    US
    MCHP
    +3.09%
    US
    AXP
    +0.11%
    US
    MCD
    +1.00%
    Wallstreetcn·
    US
    MCHP
    +3.09%
    US
    AXP
    +0.11%
    US
    MCD
    +1.00%

    Amgen (NASDAQ:AMGN) Reaches New 12-Month High - Still a Buy?

    Amgen Inc. (NASDAQ:AMGN) reached a new 52-week high, trading at $346.38. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average price target of $335.65. Recent earnings beat expectations, with a quarterly revenue increase of 12.4% year-over-year. The company announced a quarterly dividend of $2.38 per share. Insider trading activity includes significant stock sales by executives. Hedge funds have adjusted their positions in Amgen.

    Market Beat·
    US
    AMGN
    -2.68%
    Market Beat·
    US
    AMGN
    -2.68%
    © 2025 Longbridge｜Disclaimer